Observational - Registry
Consenting participants of the COMPLETE trial (Complete vs Culprit-only Revascularization Strategies to Treat Multi-vessel Disease after Primary PCI for STEMI), participants will be followed passively for an additional five to ten years after completion of the trial.
During the extended follow-up period, there will be no protocol-mandated therapies and the primary care physicians will determine treatment of all study participants based on their interpretation of the available evidence.
The follow-up will be observational and focused at identifying the occurrence of deaths and major CV events.
In addition, if possible, linkages to administrative national or regional databases that record mortality and major morbidity (e.g. hospitalizations for myocardial infraction or stroke) will be conducted.
Observational - Registry
2020 - 2030
Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI, a Professor of Medicine at McMaster University, and Director of the Interventional Cardiology program at Hamilton Health Sciences. His research focuses on the role and timing of invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antiplatelet and anticoagulant therapies in these patients.
He has led several large pragmatic randomized trials evaluating invasive interventional strategies in patients with acute coronary syndromes. He has also lead multinational randomized trials evaluating novel antiplatelet and anticoagulant therapies to improve outcomes in patients experiencing a heart attack.
Shamir Mehta has published 127 original research papers in several medical journals including The New England Journal of Medicine, The Lancet, JAMA, and Circulation. His success in research has earned him a coveted Canada’s Top 40 under 40TM award in 2004, and he has received a Canadian Institutes of Health Research New Investigator Career Award.
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
Back To Top